Pretomanid Blocks TB Ribosomal RNA While Both Drugs Kill Bacteria Similarly

Tuberculosis remains a major infectious disease challenge, and scientists are continually comparing drugs to find the most effective treatments. In new work led by corresponding author Nicholas D. Walter, researchers focused on two related drugs, delamanid and pretomanid, that are used against Mycobacterium tuberculosis. Rather than relying only on conventional measures of bacterial killing, the team asked whether the drugs differ in how they affect ribosomal rRNA synthesis, a cellular process essential to bacterial growth. The study set out to compare both bactericidal activity and an RNA-focused readout called the RS ratio. By testing multiple doses in controlled laboratory conditions and in an established animal infection model, the researchers aimed to uncover whether drugs within the same class might have meaningful mechanistic differences that standard tests miss. Reporting under the name Nicholas D. Walter, the group emphasized that examining orthogonal measures—those that look at different aspects of bacterial physiology—can reveal distinctions important for drug development and for understanding how these treatments work inside infected hosts.

To compare the two drugs side by side, the team conducted dose-ranging studies in aerobic axenic culture and in the conventional BALB/c mouse high-dose aerosol infection model. They measured both bactericidal activity and the RS ratio response for delamanid and pretomanid. The experiments showed that delamanid and pretomanid produced similar bactericidal effects when judged by conventional measures. However, the RS ratio results diverged: delamanid displayed no discernable RS ratio response, even at 16-times the human-equivalent dose, whereas higher pretomanid doses resulted in significantly greater RS ratio effects. In short, both drugs reduced bacterial counts similarly, but only pretomanid produced a strong suppression of ribosomal rRNA synthesis as detected by the RS ratio. The study concluded that delamanid and pretomanid have comparable bactericidal activity but pretomanid has superior RS ratio activity.

These findings matter because conventional CFU-based pharmacodynamics—measures of colony-forming units that count surviving bacteria—did not capture the difference seen with the RS ratio. The RS ratio appears to report on a distinct, orthogonal drug effect tied to ribosomal rRNA synthesis that one drug in the same class can strongly inhibit while the other does not. That suggests researchers and drug developers may miss important mechanistic distinctions if they rely solely on standard killing assays. Incorporating measures like the RS ratio into preclinical testing could help prioritize compounds that affect essential bacterial processes beyond simple bactericidal activity. For clinicians and scientists thinking about combinations or sterilizing potential, knowing whether a drug alters ribosomal rRNA synthesis could inform regimen design and further studies, even though additional work would be needed to link RS ratio effects directly to clinical outcomes.